Picard Medical Launches FDA-Cleared Connector Covers for SynCardia Total Artificial Heart
Key Insights
Picard Medical (search) announced the rollout of FDA-cleared CPC Connector Covers (search) for its SynCardia Total Artificial Heart (search), designed to enhance patient comfort and device safety.
The new accessory provides additional protection over metal release buttons on STAH CPC connectors that link external drivers to pneumatic drive cannulas.
Implementation begins January 15, 2026, with comprehensive staff training completed and clinical support provided to hospitals and existing patients.
Picard Medical (search), Inc. has announced the rollout of FDA-cleared Connector Covers for its SynCardia Total Artificial Heart (search) (STAH), marking a significant enhancement to the world's only commercially available total artificial heart system. The new CPC Connector Covers (search) are designed to improve patient comfort during daily activities while reinforcing the safety and reliability of the life-sustaining device.
Enhanced Safety and Comfort Features
The CPC Connector Covers (search) provide an additional layer of protection over the metal release buttons found on STAH CPC connectors, which externally connect SynCardia Drivers to the two pneumatic drive cannulas of the STAH ventricles. This design enhancement addresses practical concerns for patients living with the artificial heart system, offering improved comfort during routine activities.
"Patient safety and quality of life are central to everything we do," said Steve Langford, Senior Clinical Specialist at SynCardia Systems (search). "This enhancement reflects our ongoing commitment to practical improvements that support confidence and ease of use for both patients and clinicians."
Implementation Timeline and Training
The rollout is scheduled to be incorporated into standard clinical practice for patients in the United States beginning January 15, 2026. Picard Medical (search) has completed comprehensive preparation for the launch, with all SynCardia sales and clinical staff having completed required training in advance of the rollout.
SynCardia will work directly with hospital and clinical teams to provide training materials, implementation guidance, and support for existing patients as appropriate, ensuring seamless integration of the new accessory into current treatment protocols.
Market Leadership in Artificial Heart Technology
The SynCardia Total Artificial Heart (search) maintains its position as the only commercially available total artificial heart in the United States and Canada. The device represents a critical therapeutic option for patients with end-stage heart failure (search), serving as an implantable system that assumes the full functions of a failing or failed human heart.
With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart (search) stands as the most widely used and extensively studied artificial heart globally. The device holds the distinction of being the first artificial heart approved by both the FDA and Health Canada, establishing its regulatory precedence in the field of mechanical circulatory support.
Clinical Impact for End-Stage Heart Failure
The enhancement comes at a crucial time for patients with end-stage heart failure (search), a condition where the SynCardia Total Artificial Heart (search) serves as a bridge to transplantation or destination therapy. The addition of Connector Covers represents Picard Medical (search)'s continued focus on improving the patient experience while maintaining the device's proven safety profile and clinical efficacy.
The company's commitment to incremental improvements reflects the ongoing evolution of artificial heart technology, where patient quality of life considerations increasingly drive device refinements alongside core therapeutic functionality.